NanoMosaic Appoints Dr. Anne Marie Morse to Lead Clinical Advisory Board for Ultra-Sensitive Diagnostic Platform
核心洞察
NanoMosaic (搜索) has appointed Dr. Anne Marie Morse, an internationally recognized neurologist and sleep medicine specialist, as Chairwoman of its newly formed Clinical Advisory Board to accelerate clinical diagnostics and neurological applications.
The company's Tessie™ platform delivers laboratory-grade sensitivity at the point of need, providing femtogram-per-milliliter sensitivity and results in 7.5 seconds per sample from crude biological samples.
The portable diagnostic system enables pharmaceutical companies to identify treatment responders earlier, improving clinical trial efficiency while reducing patient burden and development risk.
NanoMosaic (搜索), Inc. announced the appointment of Dr. Anne Marie Morse as Chairwoman of its newly formed Clinical Advisory Board, marking a strategic expansion of clinical leadership to accelerate the deployment of ultra-sensitive companion diagnostics in neurology and beyond. The internationally recognized neurologist and sleep medicine specialist will collaborate with pharmaceutical partners to integrate NanoMosaic's diagnostic capabilities across the entire drug development pipeline, from early discovery and clinical trial design to regulatory approval and commercialization.
Revolutionary Diagnostic Platform Technology
Central to NanoMosaic (搜索)'s clinical strategy is the Tessie™ platform, a portable, plug-and-play diagnostic system engineered to deliver laboratory-grade sensitivity at the point of need. The system represents a significant advancement in biomarker detection capabilities, offering several breakthrough features that distinguish it from traditional laboratory-based approaches.
The Tessie platform (搜索) enables direct measurement from crude biological samples, including plasma, tears, saliva, and cerebrospinal fluid, without requiring purification steps that typically complicate and delay diagnostic processes. This capability is particularly significant for clinical applications where rapid results are critical for patient care decisions.
The system achieves femtogram-per-milliliter sensitivity for detection of ultra-low-abundance biomarkers (搜索), a level of precision that enables identification of molecular signatures that may be missed by conventional diagnostic methods. Results are delivered in 7.5 seconds per sample, supporting real-time clinical decision-making that can immediately impact patient care pathways.
Clinical Trial Optimization and Pharmaceutical Integration
The integration of Tessie into pharmaceutical development addresses critical challenges in clinical trial design and execution. By enabling ultra-sensitive biomarker assessment outside of centralized laboratory environments, the platform allows pharmaceutical companies to identify responders versus non-responders earlier in the development process, improving trial power while reducing patient burden and development risk.
The system's rapid, clean-room-free deployment with immediate plug-and-play setup supports decentralized clinical trial recruitment and population screening, potentially transforming how pharmaceutical companies approach patient identification and enrollment. This capability is particularly valuable for neurological conditions (搜索) where biomarker-driven patient selection can significantly impact trial outcomes.
Dr. Morse will help guide the deployment of NanoMosaic (搜索)'s diagnostics as scalable population health tools, enabling earlier patient identification, improved trial efficiency, and more precise delivery of therapies to patients most likely to benefit. The integration supports both clinical and commercial objectives, allowing companies to optimize trial design while simultaneously validating companion diagnostics for market adoption.
Leadership Vision and Clinical Impact
"I am incredibly excited to embrace my new role as Chair of the Clinical Advisory Board for NanoMosaic (搜索)," said Dr. Anne Marie Morse. "I envision NanoMosaic as a truly transformative force—a U.S.-based, cost-effective, and efficient platform that will elevate the standard of care in neurology and beyond. Its potential for precise diagnostics and innovative biomarker assays positions it to make a profound impact on population health while supporting the individualized patient journey."
John Boyce, Chairman and Co-Founder of NanoMosaic (搜索), emphasized the strategic importance of Dr. Morse's appointment: "Anne's leadership reinforces our mission to move precision medicine closer to patients. By enabling real-time, ultra-sensitive diagnostics outside of traditional lab settings, we can streamline how therapies reach patients, accelerate care, and alleviate suffering by getting the right treatments to the right people faster."
Clinical Expertise and Background
Dr. Anne Marie Morse brings extensive clinical and research experience to her new role. She has served as Director of Child Neurology and Pediatric Sleep Medicine, founded and led a child neurology residency program, and played a key role in digital transformation initiatives at Geisinger (搜索). Her experience spans advisory roles and principal investigator positions across numerous pharmaceutical and biotechnology organizations, complemented by recognition as an educator and patient advocate.
The appointment enables a smoother transition from clinical studies to broad population health deployment, positioning NanoMosaic (搜索)'s diagnostic platform to support precision medicine initiatives across multiple therapeutic areas while maintaining focus on neurological applications where biomarker-driven approaches can significantly impact patient outcomes.